Description
Remoqueen (Mirtazapine) 7.5 mg
Remoqueen 7.5 mg is a brand name for mirtazapine, an antidepressant medicine. The supplied product details are consistent with a mirtazapine tablet presentation, but the trade name itself is not independently verified here. This summary is based on official prescribing information for mirtazapine and supporting scientific literature.
Active Ingredient and Medicine Class
Active ingredient: mirtazapine.
Medicine class: antidepressant; commonly described as a noradrenergic and specific serotonergic antidepressant (NaSSA) and also classified as a tetracyclic antidepressant.
Established Medical Uses
Mirtazapine is approved for the treatment of major depressive disorder in adults. Regulatory labeling identifies it as an oral antidepressant for depressive disorders. Evidence from randomized trials and meta-analyses supports its efficacy in acute treatment of depression.
How It Works
Mirtazapine works by increasing noradrenergic and serotonergic activity in the brain through receptor-level effects rather than by blocking serotonin reuptake. It antagonizes certain presynaptic and postsynaptic receptors, which helps enhance neurotransmission involved in mood regulation. Its receptor profile also helps explain its sedating and appetite-related effects.
Important Safety Information
Mirtazapine is contraindicated with monoamine oxidase inhibitors (MAOIs), including linezolid and intravenous methylene blue, because of the risk of serotonin syndrome. Prescribing information also warns about suicidal thoughts and behaviors, particularly in younger patients treated with antidepressants, and about serious skin reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS. Clinically important interactions include other serotonergic medicines and drugs that may increase sedation or affect CNS function.
Possible Side Effects
Common adverse effects include drowsiness, increased appetite, weight gain, dry mouth, and dizziness. Other reported effects include constipation and fatigue. Serious but less common reactions include severe rash, blood disorders, serotonin syndrome, low sodium, abnormal heart rhythm, and rare psychiatric or movement-related effects reported after marketing.
Scientific Evidence
Systematic reviews and meta-analyses in adults with major depression show that mirtazapine is more effective than placebo and broadly comparable with several other antidepressants in short-term treatment, while adverse-event reviews confirm a pattern of sedation and weight-related effects that is clinically relevant in practice.
Medical Information Notice
This page is an educational summary based on sources available at the time of review and does not replace the official patient leaflet, product label, or individual assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration / DailyMed: Mirtazapine Tablets, Full Prescribing Information. DailyMed official prescribing information
- van Moffaert M, et al.: Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. CNS Drugs. 2009. PubMed article page
